Ironwood Pharmaceuticals (IRWD)
(Delayed Data from NSDQ)
$0.80 USD
+0.05 (7.21%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.79 -0.01 (-1.81%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IRWD 0.80 +0.05(7.21%)
Will IRWD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IRWD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRWD
Why Is Ironwood (IRWD) Down 18.4% Since Last Earnings Report?
IRWD Stock Down 15% as Q1 Earnings & Revenues Miss Estimates
IRWD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ironwood Pharmaceuticals (IRWD) Reports Q1 Loss, Misses Revenue Estimates
Vivos Therapeutics, Inc. (VVOS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates
Other News for IRWD
Vanguard Group Inc. Expands Stake in Ironwood Pharmaceuticals
Ardelyx: 'Hold' With Caution As Major Inflection Point Approaches
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
Ironwood Pharma Elects Directors at Annual Meeting